Amgen, the biotech giant based in Thousand Oaks, announced promising results for a clinical trial of its experimental migraine treatment Aimovig on April 17. The announcement was made after markets closed. According to a news release, the late-stage trial found that it “reduced episodic migraines by at least half in 30 percent of patients who…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
